Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human APX001 intravenous dose-escalation study in healthy volunteers
NL-OMON46244Phase 1Active, not recruiting
- Sponsor
- Amplyx Pharmaceuticals
- Start
- May 2016
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in mycoses, invasive candidiasis, invasive aspergillosis (IA) and 1 more comparing APX001 with Placebo (2 arms). Primary endpoint: Safety, tolerability, and pharmacokinetics of APX001. Started May 2016; status: active, not recruiting.
02
Drugs
fosmanogepix
03
Conditions
mycosesinvasive candidiasisinvasive aspergillosis (IA)Invasive Mold Infections (IMIs)
Beyond the preview
Go deeper on NL-OMON46244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46244.